InSightec Launches a Major Clinical Research Program to Conduct Human
Clinical Trials of Magnetic Resonance (MR) Guided Ultrasound Technology for
Additional Women's Health and Oncology Applications
HAIFA, Israel, November 15 /PRNewswire/ -- InSightec announced today that
it's ExAblate(R) 2000 technology will be featured in seven presentations at
the 91st Scientific Assembly and Annual Meeting of the Radiological Society
of North America (RSNA). The meeting will be held at McCormick Place in
Chicago, November 22 - December 2, 2005. The ExAblate 2000 combines magnetic
resonance imaging (MRI) with high intensity focused ultrasound to
non-invasively thermally ablate (destroy) tumors in the body. InSightec
continues to develop this leading technology approved by the FDA last year
for uterine fibroids and has launched a multi-million dollar program to
conduct human clinical trials on the technology's potential use in treating
other oncology indications including breast, bone, liver, and brain tumors
while continuing the clinical research in fertility preserving treatment of
uterine fibroids.
The ExAblate 2000 is being used in 25 sites worldwide and has treated
over 1400 women in the past year with uterine fibroids, a benign but painful
condition that affects approximately 25% of women of childbearing age. In the
oncology field, more than 130 patients with breast cancer were treated
globally under research protocols.
The ExAblate 2000 System will be exhibited at the GE Healthcare booth,
#7714 in the North Hall. Also, Fiona Fennessy's studies on uterine fibroids
have been selected by RSNA to be highlighted in a press conference on
Wednesday, November 30 (please see details below).
Following are the ExAblate 2000 talks and sessions at RSNA:
Presentation Title/Abstract Presenter Date/Time/Location
Number
Feasibility of Atsuya Okada, Sunday, November 27
Diffusion-weighted MR Imaging MD, IseiKai
and ADC Map to Predict Necrosis Hospital, 11:05 am - 11:15 am
of Uterine Fibroids during MR Osaka, Japan
Imaging-guided Focused E353A
Ultrasound Surgery (SSA06-03)
Magnetic Resonance guided Wadyslaw Sunday, November 27
focused ultrasound of Uterine Gedroyc, MD,
Fibroids: Treating Larger St. Mary's 11:55 am - 12:15 pm
Leiomyomas (SSA06-08) Hospital,
London, England E353A
Treatment Outcome in MR-guided Fiona Fennessy, Monday, November 28
Focused Ultrasound Surgery MD, Brigham and
(MRgFUS) for Uterine Fibroids: Women's 11:10 am - 11:40 am
Analysis of the Effect of Hospital,
Baseline Uterine Size and Boston, MA E253CD
Number of Fibroids (SSCO2-05)
Evaluation of symptom relief Fiona Fennessy, Monday, November 28
and fibroid reduction one year MD, Brigham and
following MR-guided Focused Women's 11:30 am - 11:40 am
Ultrasound Surgery (SSCO2-07) Hospital,
Boston, MA E253CD
Novel Breast Therapies and Dave Monday, November 28
Techniques Gianfelice, MD,
Toronto General 4:30 pm - 6:00 pm
(Invited speaker). (SFF01) Hospital, E350
Toronto,
Ontario, Canada
RSNA Press Conference: Fiona Fennessy, Wednesday,
Noninvasive Ultrasound MD, Brigham and November 30
Treatment Shrinks Fibroids Women's
Hospital, 9:45 am
Boston, MA Media Room (Level
2, Hall E)
MR guided focused ultrasound Hidemi Thursday, December 1
ablation of breast cancer Furusawa, MD,
(LPR01-04) Breastopia 12:45pm - 12:55 pm
Namba Hospital, (Poster Session -
Miyazaki, Japan Theater 2A)
Interventional Oncology Kullervo Thursday, December 1
Symposium Session: Image Hynynen, PhD 1:40 pm - 2:00 pm
guidance for Oncologic Brigham and
Intervention MR guided focused Women's S101AB
ultrasound interventions Hospital,
Boston, MA
Evaluation of Safety and Fiona Fennessy, Friday, December 2
Efficacy of a Continued Access MD, Brigham and 11:10 am - 11:20 am
Study for MR-guided Focused Women's
Ultrasound Surgery of uterine Hospital, E350
fibroids (SSTO2-05) Boston, MA
About ExAblate 2000
The ExAblate 2000 is the first U.S. Food and Drug Administration (FDA)
approved system to use the breakthrough MRgFUS technology that combines MRI -
to visualize tissues in the body, plan the treatment and monitor in real time
treatment outcome - and high intensity focused ultrasound to thermally ablate
tissue. MR thermal feedback, provided uniquely by the system, allows the
physician to control and adjust the treatment in real time to ensure that the
targeted tumor is fully treated and surrounding tissue is spared. ExAblate
received FDA approval for the treatment of symptomatic uterine fibroids in
October 2004.
Uterine fibroids are benign growths in the uterus that affect
approximately 13 million women of child bearing age in the U.S. Each year
approximately 200,000 women have hysterectomies, to treat uterine fibroids.
Unlike hysterectomy, myomectomy and UAE, this technology is completely
non-invasive using MR-guided focused ultrasound to thermally ablate (destroy)
tumors in the uterus. For women this means no hospital stay and only 1-2 days
of recovery as opposed to the one week (UAE); two weeks (myomectomy); or six
weeks (hysterectomy) usually associated with treatment of this condition.
About InSightec
InSightec Ltd. is a privately held company owned by Elbit Medical Imaging
(EMI), General Electric, MediTech Advisors, LLC and employees. It was founded
in 1999 to develop the breakthrough MR guided Focused Ultrasound technology
and transform it into the next generation operating room. Headquartered near
Haifa, Israel, the company has over 135 employees and has invested more than
$80 million in research, development, and clinical investigations. Its U.S.
headquarters are located in Dallas, Texas. For more information, please go
to: http://www.insightec.com
For more information about uterine fibroids, please visit
http://www.uterine-fibroids.org
Contact Information
InSightec Ltd.
Tel: +972-4-813-1313
Email: info@insightec.com
For media inquiries, contact:
Fern Lazar
Lazar Partners, Ltd.
Tel: +1-212-867-1762
Email: flazar@lazarpartners.com
SOURCE InSightec Ltd.
 back to top
CONTACT:
InSightec Ltd.: Tel: +972-4-813-1313, Email:
info@insightec.com. Fern Lazar, Lazar Partners, Ltd., Tel:
+1-212-867-1762, Email: flazar@lazarpartners.com
|
